Endocare Approved for Nasdaq Listing

Endocare, an Irvine, CA-based company focused on tissue and tumor ablation, has been approved for listing on Nasdaq. The company’s common stock will commence trading on The Nasdaq Capital Market under the symbol “ENDO” beginning tomorrow, October 10, 2007.

Craig Davenport, Endocare’s CEO, said in a statement, “Our listing on Nasdaq is a significant milestone for Endocare, marking the completion of a long turnaround process. We believe that the Nasdaq listing should help us attract a broader audience of potential investors, resulting in a more liquid security and enhanced stockholder value over time.”

The comments are closed.